Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin + Cytokine-Induced Killer cells
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of two chemotherapy agents (gemcitabine and cisplatin) plus adoptive cell immunotherapy with Cytokine-Induced Killer (CIK) cells. CIK cells are a heterogeneous population of immune effector cells with both T-cell and NK-cell properties, generated by ex vivo expansion of peripheral blood mononuclear cells with cytokines. This combination leverages both direct cytotoxic effects of chemotherapy and the immune-mediated anti-tumor activity of CIK cells, which can recognize and kill tumor cells through MHC-restricted and MHC-unrestricted mechanisms.
- Other names
- gemcitabine + cisplatin + CIK cellsGC regimen plus CIK immunotherapy
02
Targets
NCR3LG1 (Natural cytotoxicity triggering receptor 3 ligand 1)MICB (Major histocompatibility complex class i-related protein B)RNR (Ribonucleotide reductase)MHC I (MHC class I})ICAM1 (Intercellular Adhesion Molecule 1)DNA
Beyond the preview
Go deeper on gemcitabine + cisplatin + Cytokine-Induced Killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin + Cytokine-Induced Killer cells.